BioWorld

Oct. 21, 2004

View Archived Issues

Genzyme Beats Estimates With Product Sales, Curbed Expenses

Genzyme Corp. reported third-quarter numbers that beat consensus estimates, and the diversification plans the company put in place over the past year are taking hold, it said. (BioWorld Today) Read More

Personalized Medicine Coalition Formed To Benefit Health Care

Read More

UN Urged Not To Consider Ban On Stem Cell Research

Read More

BioWorld RNAi Report 2005

Read More

Other News To Note

Read More